Clonal Hematopoiesis of Indeterminate Potential in Crohn's Disease and Ulcerative Colitis.

Background: Clonal hematopoiesis of indeterminate potential (CHIP) is the presence of somatic mutations in myeloid and lymphoid malignancy genes in the blood cells of individuals without a hematologic malignancy. Inflammation is hypothesized to be a key mediator in the progression of CHIP to hematologic malignancy and patients with CHIP have a high prevalence of inflammatory diseases. This study aimed to identify the prevalence and characteristics of CHIP in patients with inflammatory bowel disease (IBD).

Ten years of experience with ruxolitinib since approval for polycythemia vera: A review of clinical efficacy and safety.

The oral Janus kinase (JAK) 1/JAK2 inhibitor ruxolitinib was approved by the US Food and Drug Administration in 2014 for treatment of patients with polycythemia vera (PV) who have an inadequate response to or intolerance of hydroxyurea (HU). PV is a chronic myeloproliferative neoplasm defined by primary absolute erythrocytosis, bone marrow hypercellularity, and JAK mutations such as JAK2V617F. Patients with PV experience burdensome symptoms and are at risk of thromboembolic events, in particular those with resistance to or intolerance of initial treatments such as HU.

Assessing pesticide residue levels in sweetpotato roots and slips treated with fungicides for management of southern blight and circular spot disease caused by .

Since 1971, North Carolina (NC) has been the leading sweetpotato-producing state in the United States (US) and is now producing more than half of the nation's annual output. Due to the high demand for US sweetpotatoes from international markets, NC allocates roughly 40% of its sweetpotatoes for export. However, low fungicide residue limits in primary export markets restricts the ability for NC producers to apply fungicides for disease management during sweetpotato production.